• All Courts
  • Federal Courts
  • Bankruptcies
  • PTAB
  • ITC
Track Search
Export
Download All
Active Filters1
Displaying 39-53 of 68 results

1018 Exhibit: Ex 1018 US 5834495

Document IPR2021-01132, No. 1018-19 Exhibit - Ex 1018 US 5834495 (P.T.A.B. Jun. 17, 2021)
The combined organic phases were washed with water and evaporated to give the free base of the title compound in 700 g yield.
The reac­ tion mixture was stirred until a clear solution was obtained, then the methylene chloride phase was separated and washed twice with water (2 1).
The solution was slowly cooled under stirring to 5°-10° C. and the precipitate was collected by filtration and dried to give the desired product in 980 g (90%) yield.
Recrystallization from warm (80° C.) 2-propanol (5 1) added activated carbon (10 g) gave after filtration and cooling to 5°-10° C. pure crystals of the title compound.
A method of treating cognitive dysfunction caused by Alzheimer’s disease in a mammal comprising administering an effective amount of the compound according to claim 1.
cite Cite Document
Analyze

1023 Exhibit: Ex 1023 Pharmeuropa 2000

Document IPR2021-01132, No. 1023-24 Exhibit - Ex 1023 Pharmeuropa 2000 (P.T.A.B. Jun. 17, 2021)
Log in to see more
cite Cite Document
Analyze

1024 Exhibit: Ex 1024 Aakeroy

Document IPR2021-01132, No. 1024-25 Exhibit - Ex 1024 Aakeroy (P.T.A.B. Jun. 17, 2021)
Log in to see more
cite Cite Document
Analyze

1014 Exhibit: Ex 1014 Morris

Document IPR2021-01132, No. 1014-15 Exhibit - Ex 1014 Morris (P.T.A.B. Jun. 17, 2021)
Log in to see more
cite Cite Document
Analyze

1007 Exhibit: Ex 1007 550 PH Part 1 of 2

Document IPR2021-01132, No. 1007-7 Exhibit - Ex 1007 550 PH Part 1 of 2 (P.T.A.B. Jun. 17, 2021)
Log in to see more
cite Cite Document
Analyze

1001 Exhibit: Ex 1001 927 patent

Document IPR2021-01132, No. 1001 Exhibit - Ex 1001 927 patent (P.T.A.B. Jun. 17, 2021)
Log in to see more
cite Cite Document
Analyze

1005 Exhibit: Ex 1005 Coe

Document IPR2021-01132, No. 1005 Exhibit - Ex 1005 Coe (P.T.A.B. Jun. 17, 2021)

cite Cite Document
Analyze

1023 Exhibit: Ex 1023 Pharmeuropa 2000

Document IPR2021-01132, No. 1023 Exhibit - Ex 1023 Pharmeuropa 2000 (P.T.A.B. Jun. 17, 2021)

cite Cite Document
Analyze

1008 Exhibit: Ex 1008 CA 2467490

Document IPR2021-01132, No. 1008 Exhibit - Ex 1008 CA 2467490 (P.T.A.B. Jun. 17, 2021)

cite Cite Document
Analyze

1021 Exhibit: Ex 1021 US 6794388

Document IPR2021-01132, No. 1021 Exhibit - Ex 1021 US 6794388 (P.T.A.B. Jun. 17, 2021)

cite Cite Document
Analyze

1024 Exhibit: Ex 1024 Aakeroy

Document IPR2021-01132, No. 1024 Exhibit - Ex 1024 Aakeroy (P.T.A.B. Jun. 17, 2021)

cite Cite Document
Analyze

1014 Exhibit: Ex 1014 Morris

Document IPR2021-01132, No. 1014 Exhibit - Ex 1014 Morris (P.T.A.B. Jun. 17, 2021)

cite Cite Document
Analyze

1006 Exhibit: Ex 1006 US 6410550

Document IPR2021-01132, No. 1006 Exhibit - Ex 1006 US 6410550 (P.T.A.B. Jun. 17, 2021)

cite Cite Document
Analyze

1003 Exhibit: Ex 1003 Gould CV

Document IPR2021-01132, No. 1003 Exhibit - Ex 1003 Gould CV (P.T.A.B. Jun. 17, 2021)

cite Cite Document
Analyze

1010 Exhibit: Ex 1010 Gould

Document IPR2021-01132, No. 1010 Exhibit - Ex 1010 Gould (P.T.A.B. Jun. 17, 2021)

cite Cite Document
Analyze
<< 1 2 3 4 5 >>